融創(01918.HK)境外債重組獲香港法院批准 股價一度升12%
融創中國(01918.HK)境外債重組計劃,今早(5日)在香港法院進行聆訊,已獲法院批准。
融創上月的債權人會議已通過相關方案,合共2,019名債權人投票,債權人數通過比率為99.75%,債務總額通過比率為98.3%。今次獲香港法院批准,成為首間掃除相關障礙的主要內房商,同業如中國恆大(03333.HK)等,仍在尋求可行的債務重組路線圖。
融創中國早前披露,透過提高強制可轉換債券限額等方案,削減債務總額合計超過45億美元,將大幅縮減整體債務規模、緩和流動性壓力。
融創中國上午最高見2.31元,升12.1%,中午收報2.26元,升0.2元或9.71%,成交2,469.1萬股,涉資5,442.24萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.